<DOC>
	<DOCNO>NCT00724893</DOCNO>
	<brief_summary>Treatment compliance key success factor obtain full benefit Pegetron ( peginterferon alfa-2b [ PegIFN-2b ] plus ribavirin combination ) therapy patient . Treatment-naïve patient chronic hepatitis C ( CHC ) Canada Pegetron Redipen prescribe receive Pegetron Redipen therapy accordance approve labeling . The study assess effect newly approve Pegetron Redipen treatment compliance effect sustain virologic response rate . Sustained virologic response define negative hepatitis C virus ribonucleic acid ( HCV-RNA ) six month post-treatment .</brief_summary>
	<brief_title>Efficacy Pegetron® Redipen™ Treatment Treatment Compliance Patients With Chronic Hepatitis C Canada ( P04423 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Treatmentnaïve patient chronic hepatitis C Adults ( &gt; 18 year age ) Prescribed Pegetron Redipen Must meet requirement treatment Pegetron Redipen Must able obtain reimbursement medication private provincial coverage Active hepatitis B virus ( HBV ) infection ( hepatitis B surface antigen [ HBsAg ] positive ) HIV antibody positive Post liver transplant patient Any exclusion criterion per product Monograph</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>